Merck ROE 2006-2018 | MRK

Current and historical return on equity (ROE) values for Merck (MRK) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Merck ROE for the three months ending September 30, 2018 was 34.48%.
Merck ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-09-30 $3.35B $32.66B 10.00%
2018-06-30 $1.34B $32.77B 3.84%
2018-03-31 $1.58B $33.90B 4.31%
2017-12-31 $2.39B $34.57B 6.26%
2017-09-30 $2.85B $38.50B 7.18%
2017-06-30 $5.09B $39.71B 12.40%
2017-03-31 $4.35B $40.09B 10.36%
2016-12-31 $3.92B $40.31B 9.14%
2016-09-30 $5.49B $43.96B 12.47%
2016-06-30 $5.13B $43.45B 11.55%
2016-03-31 $4.61B $43.90B 10.20%
2015-12-31 $4.44B $44.77B 9.60%
2015-09-30 $10.78B $45.68B 22.82%
2015-06-30 $9.85B $46.64B 20.88%
2015-03-31 $11.17B $47.92B 23.44%
2014-12-31 $11.92B $48.79B 24.42%
2014-09-30 $5.39B $45.36B 10.84%
2014-06-30 $5.61B $48.52B 11.04%
2014-03-31 $4.52B $52.56B 8.81%
2013-12-31 $4.40B $52.33B 8.47%
2013-09-30 $4.53B $50.01B 8.58%
2013-06-30 $5.14B $50.11B 9.36%
2013-03-31 $6.02B $55.61B 10.61%
2012-12-31 $6.17B $55.46B 10.78%
2012-09-30 $6.76B $58.21B 11.75%
2012-06-30 $6.72B $57.67B 11.71%
2012-03-31 $6.95B $57.31B 12.10%
2011-12-31 $6.26B $56.94B 10.91%
2011-09-30 $4.22B $57.60B 7.36%
2011-06-30 $2.87B $57.92B 5.00%
2011-03-31 $1.60B $56.84B 2.80%
2010-12-31 $0.86B $56.81B 1.48%
2010-09-30 $7.84B $58.05B 13.20%
2010-06-30 $10.92B $57.67B 21.33%
2010-03-31 $11.73B $60.34B 27.60%
2009-12-31 $12.85B $61.49B 39.07%
2009-09-30 $8.03B $25.35B 35.19%
2009-06-30 $5.70B $22.74B 26.66%
2009-03-31 $5.91B $22.00B 28.48%
2008-12-31 $7.79B $21.17B 38.69%
2008-09-30 $4.53B $19.57B 23.34%
2008-06-30 $4.96B $20.26B 25.20%
2008-03-31 $4.87B $19.52B 24.99%
2007-12-31 $3.27B $18.19B 17.00%
2007-09-30 $5.38B $20.72B 28.23%
2007-06-30 $4.80B $19.47B 25.64%
2007-03-31 $4.62B $18.48B 24.75%
2006-12-31 $4.43B $17.56B 23.65%
2006-09-30 $5.08B $19.29B 26.95%
2006-06-30 $5.56B $19.30B 30.09%
2006-03-31 $4.78B $18.85B 26.57%
2005-12-31 $4.63B $17.98B 26.17%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $205.072B $40.122B
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $391.677B 18.36
Pfizer (PFE) United States $259.009B 14.60
Novartis AG (NVS) Switzerland $203.357B 17.38
AbbVie (ABBV) United States $137.681B 12.22
Eli Lilly (LLY) United States $120.583B 21.20
Sanofi (SNY) France $113.115B 14.01
Novo Nordisk (NVO) Denmark $107.931B 17.53
AstraZeneca (AZN) United Kingdom $103.013B 12.79
GlaxoSmithKline (GSK) United Kingdom $100.041B 13.45
Bristol-Myers Squibb (BMY) United States $88.253B 14.53